AdnectinsTM are a new family of therapeutic proteins based on the 10th fibronectin type III
domain, and designed to bind with high affinity and specificity to therapeutically relevant …

Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role
in protein engineering among the high-throughput display methodologies that have been …

The 10th type III domain of human fibronectin (Fn3) has been validated as an effective
scaffold for molecular recognition. In the current work, it was desired to improve the …

We determined the crystal structure of 1TM-αVβ3, which represents the complete
unconstrained ectodomain plus short C-terminal transmembrane stretches of the αV and β3 …

Integrins are important therapeutic targets. However, current RGD-based anti-integrin drugs
are also partial agonists, inducing conformational changes that trigger potentially fatal …

There is a critical need for compounds that target cell surface integrin receptors for
applications in cancer therapy and diagnosis. We used directed evolution to engineer the …

The αvβ3 integrin receptor is an important cancer target due to its overexpression on many
solid tumors and the tumor neovasculature and its role in metastasis and angiogenesis. We …

The 10th human fibronectin type III domain (10Fn3) is one of several protein scaffolds used
to design and select families of proteins that bind with high affinity and specificity to …

In the ten years since the first fibronectin type III (FN3) domain library was published, FN3
has continued to show promise as a scaffold for the generation of stable protein domains …

The tenth human fibronectin type three domain (10Fn3) is a small (10 kDa), extremely stable
and soluble protein with an immunoglobulin-like fold, but without cysteine residues …